Face transplantation -- at least in the near-term -- may not cost much more than the multiple conventional reconstructive surgeries that a complex case would need, according to the team that did the first U.S. face transplant.
That near-total face transplant done in 2008 for a woman injured by a shotgun blast cost $349,959 compared with $353,480 for the 23 separate conventional reconstructions she had done before transplantation.
The post-transplant costs added an extra $115,463, but the overall cost was "similar," said Dr. Maria Siemionow, the reconstructive surgeon who led the transplant team at the Cleveland Clinic.
Read this story on www.medpagetoday.com.
Moreover, the piecemeal reconstructions hadn't offered good results, Siemionow and colleagues reported online in the American Journal of Transplantation.
"Although the cost of facial transplantation is considerable, the alleviation of psychological and physiological suffering, exceptional functional recovery, and fulfillment of long-lasting hope for social reintegration may be priceless," the group wrote.
The 46-year-old woman had lost her nose and palate in the injury and had been unable to breathe, smell, taste, or eat normally. She remained so disfigured that she reportedly wouldn't go out in public despite four years of reconstructive surgeries.
The transplant from a dead donor replaced 80% of her face, including the cheeks, lower eyelids, nose, and upper lip as well as cheek and maxillary bone and some upper teeth.
The world's first partial facial transplant had been done in France in 2005 for a dog attack victim. The success of the French and U.S. cases spurred further facial transplantations, including the world's first total face transplant in Spain in 2010.
Siemionow's group had called for consideration of face transplantation as first-line treatment for severe facial trauma.
But, they noted in the journal article, "As face transplantation moves further away from the questions of 'can we?' or 'should we?', the question of fiscal responsibility will soon move into the forefront and may likely become the central issue of the face transplant debate."
To address that issue, Siemionow and colleagues detailed the costs for their case.
Inpatient costs were estimated to be 25.5 percent higher than for the conventional reconstructions the patient had prior to transplant.
The biggest components were surgical costs -- 42 percent for the face transplant and 38.5 percent for the conventional reconstructions -- and nursing costs, 19.7 percent for the transplant versus 27 percent for the conventional surgeries.
Pharmacy costs, though, were doubled with face transplantation at $38,574 (16.6 percent of total costs) compared with $16,581 (8 percent of total) for reconstruction.
Immunosuppression -- required to prevent graft rejection -- was the major reason for the difference at a total direct cost of $21,506 for the regimen of antithymocyte immunoglobulin, granulocyte stimulating factor, tacrolimus, mycophenolate mofetil, and steroids for varying durations.
However, these cost comparisons include only the early period, the researchers noted.
Chronic immunosuppression for other transplant types ranges from $10,000 to $20,000 a year, so life-long immunosuppression for the face transplant patient could add up to $370,000 to $518,000.
Although long-term immunosuppression carries risks, the consequences of facial graft failure remain unknown.